Understanding ovarian reserve testing and AMH levels

Ovarian reserve refers to the quantity of eggs remaining in a woman's ovaries and is one of the key indicators that fertility specialists use when evaluating reproductive potential. Unlike men, who produce sperm continuously throughout adulthood, women are born with a finite number of oocytes, and this supply declines steadily across the lifespan. The rate of decline varies considerably from person to person, which is why direct measurement rather than age alone offers a clearer picture for those planning ahead.

Several hormones and ultrasound markers are used to assess this reserve, but Anti-Müllerian Hormone, often shortened to AMH, has become the most widely used single blood marker. Because AMH is produced by the small antral follicles in the ovaries, it correlates closely with the number of eggs available for stimulation. Combined with antral follicle counts on ultrasound and additional hormone tests, it forms the backbone of a modern fertility assessment in clinics worldwide.

For Australian women, testing has become easier to access, although costs and rebates still vary. A standard AMH blood test can be ordered by a general practitioner in Sydney, Melbourne, Brisbane, Perth, or regional centres, with results typically returning within a week. Medicare rebates apply to some related investigations, while AMH itself has not always been subsidised, leaving out-of-pocket expenses that depend on the pathology provider and clinical indication.

The decision to test is often prompted by a specific life event or a long-held plan: a couple trying to conceive without success, a woman in her mid-thirties thinking ahead, or someone preparing for medical treatment that may affect fertility. Understanding what the numbers actually mean helps turn a routine blood test into a useful planning tool rather than a source of unnecessary anxiety. The sections below explain what ovarian reserve testing involves, how values are interpreted, and the practical steps Australian patients can take next.

What ovarian reserve testing actually measures

An ovarian reserve test does not directly count eggs. Instead, it estimates how many microscopic follicles containing immature eggs are present in the ovaries at a given moment. The most common tools are serum AMH, antral follicle count measured by transvaginal ultrasound, day-two or day-three follicle-stimulating hormone (FSH), and estradiol. Each gives a different window into ovarian function, which is why fertility specialists rarely rely on a single value alone.

AMH has gained popularity because levels stay relatively stable throughout the menstrual cycle, so the blood draw does not need to be timed to a particular day. This convenience, along with a clear link to follicle numbers, has made it the first-line test in many Australian clinics, including those attached to hospital networks and private practices. Patients in Adelaide can usually complete an AMH test, an ultrasound, and a specialist consultation within a fortnight.

These tests measure quantity rather than quality. Egg quality declines with age, primarily because of accumulated genetic changes in eggs over time, and no blood test can fully capture that. A healthy AMH result in a 38-year-old does not guarantee healthy embryos, just as a low AMH in a 28-year-old does not automatically mean pregnancy will be difficult. The result is a probability estimate, not a verdict on individual outcomes.

Interpreting AMH levels in real numbers

AMH is reported in picomoles per litre in Australia, although nanograms per millilitre is used in some other regions. General reference ranges place very low values under about 5 pmol/L, low-normal values between roughly 5 and 15 pmol/L, normal values from about 15 to 35 pmol/L, and high values above that, sometimes reaching 70 pmol/L or more in women with polycystic ovary syndrome. The exact numbers matter less than the trend, the clinical context, and the patient's age.

A higher AMH generally indicates a larger pool of recruitable follicles and a better response to stimulation medication during IVF. A lower AMH suggests a smaller pool and a potentially lower number of eggs retrieved, which can affect the number of embryos available for transfer or freezing. Clinics in Brisbane and Sydney routinely see results across the entire spectrum within a single week and tailor stimulation protocols accordingly.

A very low reading, sometimes called diminished ovarian reserve, signals that time may be a critical factor. For women under 35, the prognosis is usually more favourable than for those over 40, because younger eggs are statistically more likely to be chromosomally normal. For women over 40, even a normal AMH does not fully offset age-related declines in egg quality, which is why specialists combine AMH with other markers and a candid discussion about realistic outcomes.

Tests commonly paired with AMH

An antral follicle count is performed during a transvaginal ultrasound and provides a visual count of follicles between 2 and 10 millimetres in size. The number correlates well with AMH and gives the specialist a tangible picture to discuss during the same appointment. In centres across Australia, AFC is often bundled with AMH in an initial fertility work-up because together they refine the estimate of ovarian response.

Day-three FSH and estradiol are older markers that some clinics still use alongside AMH. Elevated FSH, particularly above 10 IU/L, can suggest reduced ovarian reserve, although the test must be performed at the start of a menstrual cycle to be meaningful. Estradiol helps determine whether an elevated FSH result is being suppressed by other hormones, which would otherwise make the FSH value look deceptively normal.

For couples with additional concerns, further tests may include thyroid function, prolactin, vitamin D, and a semen analysis for the male partner. Around one-third of infertility in Australia is attributed to female factors, one-third to male factors, and the remaining third to a combination or unexplained causes, according to data from the Australia and New Zealand Assisted Reproduction Database. A comprehensive work-up saves time and helps focus treatment planning.

Lifestyle and age factors that influence the picture

Age remains the single strongest predictor of natural conception and IVF success, even when AMH is reassuring. Egg quality gradually falls across the thirties and more sharply after 37 or 38, regardless of how many eggs remain. This is why a 25-year-old with a low AMH often has better natural conception chances than a 40-year-old with a normal reading, despite the apparent contradiction in the numbers.

Lifestyle factors also matter. Smoking accelerates the loss of ovarian follicles and is consistently linked to earlier menopause, while heavy alcohol intake, poor sleep, and significant weight fluctuations can affect hormone balance. Australian guidelines encourage women planning pregnancy to address these factors before trying, alongside routine preconception care such as folate supplementation and a medication review.

For women with conditions such as endometriosis, prior ovarian surgery, or a history of chemotherapy, the reserve may be lower than expected for age, and testing is recommended earlier. In Melbourne and Sydney, multidisciplinary teams that include gynaecologists, endocrinologists, and reproductive specialists coordinate complex care, particularly when treatment overlaps with other medical needs.

When Australian women tend to seek testing

Common triggers include actively trying to conceive for twelve months without success, or six months if aged 35 or older. Other triggers include irregular cycles, prior ovarian surgery, endometriosis, chemotherapy exposure, or a family history of early menopause. Women who simply want to plan ahead, including those considering egg freezing in their early to mid-thirties, also form a growing share of patients seen in fertility clinics from Perth to Hobart.

Another trigger is the use of medications that may affect fertility, such as long-term hormonal treatments or therapies for autoimmune conditions. Oncologists in major Australian centres routinely refer patients of reproductive age to fertility specialists before starting chemotherapy, so egg or embryo freezing can be arranged within tight timelines. Pre-treatment counselling has become standard in most large hospitals.

Social trends also play a role. Australian Bureau of Statistics data shows that the average age of mothers has risen steadily over recent decades, with first-time mothers now commonly in their early thirties in cities like Sydney and Melbourne. This shift has pushed more women to think about fertility proactively, including baseline AMH testing even before they try to conceive.

What to do with results and how Australia covers testing

After testing, the next step is usually a consultation with a fertility specialist, sometimes called a reproductive endocrinologist. A growing number of clinics in capital cities offer bulk-billed initial specialist visits under Medicare, although rebates for AMH itself have changed over time and currently vary by pathology provider and clinical indication. Patients are encouraged to confirm rebates with their GP and the testing laboratory before having blood drawn.

Treatment options following a low or borderline result may include lifestyle optimisation, timed intercourse, ovulation induction, intrauterine insemination, IVF, or, for those wishing to preserve future options, egg freezing. Looking at gentler stimulation protocols can be particularly useful when the reserve is reduced, as lower-dose cycles sometimes yield similar egg numbers with fewer medications.

For a high AMH or polycystic ovary syndrome profile, the focus typically shifts to managing ovulation, metabolic health, and the risk of ovarian hyperstimulation during IVF. Lifestyle factors such as weight, smoking status, alcohol intake, and sleep all influence outcomes, and Australian guidelines consistently recommend addressing these before and during treatment. Quitting smoking can improve both natural conception rates and IVF success.

Cost remains a real consideration. A single IVF cycle in Australia commonly ranges from roughly AUD 8,000 to AUD 12,000 out of pocket, depending on the clinic, medications, and rebates from Medicare and private health insurance. Some clinics offer payment plans, and a small number of public services provide subsidised cycles for eligible patients. Discussing these details openly with the treating team helps avoid financial surprises.

Ovarian reserve testing, with AMH at its centre, offers a window into reproductive biology that previous generations simply did not have. It cannot predict pregnancy with certainty or replace age-based counselling, but it adds meaningful detail to the conversation between a patient and her care team. Used thoughtfully, it can guide decisions about timing, treatment intensity, and fertility preservation.

For Australian women and couples, the practical message is straightforward. Book a long appointment with a GP or fertility specialist to discuss goals, history, and the tests that make sense. Ask about Medicare rebates and out-of-pocket costs upfront. Bring a list of questions and, where helpful, a partner or support person. These small steps turn a complex topic into a manageable plan.

If you would like expert guidance grounded in advanced laboratory technology and individualised treatment planning, the team at Indo Nippon IVF in Mumbai supports patients from across India and overseas, including Australian travellers seeking tailored care. Reach out for a personalised consultation and start mapping the path that fits your circumstances, timeline, and family-building goals today.